Advance Online
Elderly Asian woman and Black man embracing and smiling outside.
Advance Online

FDA Approves SPEVIGO® for Adults with GPP

The first FDA approved treatment for generalized pustular psoriasis.

On September 1, 2022, the U.S. Food and Drug Administration (FDA) approved SPEVIGO® (spesolimab-sbzo) Injection for the treatment of adults with generalized pustular psoriasis (GPP). SPEVIGO®, the first and only treatment approved specifically for GPP, is a novel antibody that blocks the activation of the interleukin 36 receptor (IL-36R). The interleukin 36 signaling pathway, part of the immune system, has been shown to be involved in causing GPP flares. [1]

In GPP, also known as von Zumbusch psoriasis, pustules often cover large areas of the body and typically presents with fever, shivers, intense itching, a rapid pulse, fatigue, headache, nausea, muscle weakness, and joint pain. People with GPP tend to have sudden flares that can last for several weeks, and can cause life-threatening complications, such as a sudden drop in blood pressure. [2]

The approval of SPEVIGO® was based on the 12-week Effisayil 1 clinical trial, where patients received SPEVIGO® intravenously or placebo during a GPP flare. Over half of patients treated with SPEVIGO® had no visible pustules after one week, compared to placebo (6%). [1]

About 3% of people living with psoriasis develop pustular psoriasis, and it is estimated that GPP has a worldwide incidence of 2 to 7 per million people. Because GPP is such a rare type of the disease, it can be difficult to diagnose, often causing delays in treatment. [3, 4]

Pustular Psoriasis Resource Center

NPF is here to help with resources, advice and stories specifically for you to help live the healthy and happy life that you want.

Go to the Pustular Psoriasis Resource Center


1. FDA approves the first treatment option for generalized pustular psoriasis flares in adults. Boehringer Ingelheim.



4. Menter, A., Van Voorhees, A.S. & Hsu, S. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.Dermatol Ther (Heidelb) 11, 1917–1929 (2021).

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logoTwill Care logo

Copyright © 1996-2022 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.